Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer
NCT06203821Phase 1Not yet recruiting
- Start
- Sep 2026
- Primary completion
- May 2027
- Modality
- Prophylactic Vaccines, IgG Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of np137 in pancreatic ductal adenocarcinoma (PDAC). Primary endpoint: Primary tumor MAK's Signature Epithelial-to-Mesenchymal Transition (EMT) Mean Score. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
np137
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06203821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06203821.